Cystitis
Cystitis is an infection of the bladder or lower urinary tract, commonly caused by bacteria from the fecal or vaginal flora entering the urethra, and often presents with urinary symptoms such as dysuria. Interstitial cystitis (IC), a type of bladder pain syndrome, involves chronic bladder and pelvic pain with symptoms like urgency, frequent urination, and pain during sex, and is associated with conditions like irritable bowel syndrome and fibromyalgia.
Health Outcomes
- Absence of Bacteremia
- Adverse Safety Concern from Antimicrobial Resistance
- Delayed Onset of Urinary Tract Infections
- Development of Pyuria
- Enhanced Bacterial Growth
- Enhanced Resistance to E. coli
- Genitourinary Adverse Events
- Improved Antibacterial Activity
- Improved Antibiotic Sensitivity
- Improved Dysuria
- Improved Genitourinary Symptoms
- Improved Lactobacillus Counts
- Improved Microbial Safety
- Improved Niche Colonization
- Improved Symptoms of Acute Uncomplicated Cystitis
- Improved Urinary Frequency
- Improved Urogenital Tract Health
- Improved Vaginal Cornification
- Increased Antibacterial Compound Production
- Increased Cultivable Lactobacilli
- Increased Escherichia Coli Levels
- Increased Incidence of Pyuria
- Increased Levels of Lactobacillus Paracasei/Casei
- Inhibited ESBL-Positive Escherichia Coli Growth
- Mild Urinary Tract Inflammation
- Occurrence of Unrelated Haematuria
- Potentially Effective Antibacterial Proteins
- Presence of Pyuria
- Protected Bladder Microbiome
- Reduced Acute Cystitis Episode
- Reduced Adhesion of Escherichia coli
- Reduced Bacterial Infection Severity
- Reduced Bacterial Motility
- Reduced Cefotaxime-Resistant Enterobacterales Abundance
- Reduced Coliform Bacteria Levels
- Reduced Coliform Counts
- Reduced Defense Gene Activity for Gram-Negative Pathogens
- Reduced Dysuria
- Reduced ESBL-Producing Escherichia Coli Colonization
- Reduced Escherichia Coli Levels
- Reduced Escherichia coli Growth
- Reduced Fecal Coliform Levels
- Reduced Genitourinary Discomfort
- Reduced Gram-Negative Bacteria Levels
- Reduced Harmful Bacterial Populations
- Reduced Impact of Gram-negative Microorganisms
- Reduced Incidence of Side Infections during Antibiotic Treatments
- Reduced Infection Recurrence
- Reduced Localized Infection
- Reduced Mucin Adhesion
- Reduced Organ Injury from Escherichia coli
- Reduced Pathogen Adhesion
- Reduced Pathogenic Bacillus Cereus Levels
- Reduced Pathogenic Bacteria
- Reduced Potential Pathogenic Bacteria
- Reduced Pseudomonas Levels
- Reduced Pyelonephritis Episode
- Reduced Recurrence of Urinary Tract Infections
- Reduced Recurrent UTI
- Reduced Staphylococcus Aureus Virulence
- Reduced Suprapubic Pain
- Reduced Transmission of Antibiotic-Resistant Genes
- Reduced Urinary Tract Infection Incidence
- Reduced Urinary Tract Infection Symptoms
- Reduced Urinary Tract Inflammation
- Reduced Urinary Urgency
- Reduced Urine Dipstick Markers of Urinary Tract Infection
- Reduced Urogenital Infections
- Reduced Urogenital Pathogen Growth
- Reduced Uropathogenic Bacterial Adhesion
- Reduced Visceral Pain
- Stable Enterobacterial Numbers